Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON MENSAH

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1619137593
CMS profile
836183
Location
BEAUMONT, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$10,877.06

129 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON MENSAH

NPI 1619137593 · CMS profile ID 836183

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

BEAUMONT, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619137593?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON MENSAH, NPI 1619137593, CMS profile ID 836183. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619137593?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JASON MENSAH, NPI 1619137593, CMS profile ID 836183. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619137593?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JASON MENSAH, NPI 1619137593, CMS profile ID 836183, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1619137593?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

129 matching records · $10,877.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 129 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 129.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $15.3609/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719192369 CMS
Adlon Therapeutics L.P. $11.2509/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749347999 CMS
ITI, Inc. $20.7809/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750034817 CMS
Lundbeck LLC $20.0209/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747553173 CMS
Merck Sharp & Dohme Corporation $12.0709/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747663413 CMS
Lundbeck LLC $14.2909/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747553169 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.9809/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747266065 CMS
Teva Pharmaceuticals USA, Inc. $16.5309/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749562715 CMS
Teva Pharmaceuticals USA, Inc. $4.8409/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749562787 CMS
Otsuka America Pharmaceutical, Inc. $11.3709/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756483 CMS
Otsuka America Pharmaceutical, Inc. $13.2109/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756479 CMS
Allergan, Inc. $13.2408/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723761711 CMS
Tris Pharma Inc $15.2308/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751459677 CMS
Janssen Pharmaceuticals, Inc $15.8208/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719192385 CMS
Indivior Inc. $12.9908/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752770081 CMS
Lundbeck LLC $12.9708/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747553165 CMS
Neurocrine Biosciences, Inc. $6.8608/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748931489 CMS
Lundbeck LLC $14.8108/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747553161 CMS
Otsuka America Pharmaceutical, Inc. $14.2608/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756475 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.0408/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747266063 CMS
Tris Pharma Inc $18.1908/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751459663 CMS
Lundbeck LLC $11.5508/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747553157 CMS
ITI, Inc. $12.3307/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750034815 CMS
Otsuka America Pharmaceutical, Inc. $16.5207/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756469 CMS
Janssen Pharmaceuticals, Inc $19.8407/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719192387 CMS
Otsuka America Pharmaceutical, Inc. $13.6207/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756465 CMS
Allergan, Inc. $11.9707/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723761709 CMS
Indivior Inc. $11.7107/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752770079 CMS
Neurocrine Biosciences, Inc. $20.4407/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748931487 CMS
Teva Pharmaceuticals USA, Inc. $6.2307/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749468267 CMS
Teva Pharmaceuticals USA, Inc. $14.3707/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749462685 CMS
Otsuka America Pharmaceutical, Inc. $14.8307/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756463 CMS
Lundbeck LLC $16.3507/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747553153 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.4507/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747266061 CMS
Otsuka America Pharmaceutical, Inc. $24.7307/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756459 CMS
Otsuka America Pharmaceutical, Inc. $16.3907/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756451 CMS
Otsuka America Pharmaceutical, Inc. $13.6707/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756455 CMS
Neurocrine Biosciences, Inc. $26.0206/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748931485 CMS
Allergan, Inc. $7.1506/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723761707 CMS
Otsuka America Pharmaceutical, Inc. $2.6506/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756447 CMS
Otsuka America Pharmaceutical, Inc. $3.0206/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748756443 CMS
Lundbeck LLC $20.3606/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747553147 CMS
Adlon Therapeutics L.P. $10.9906/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749347991 CMS
Teva Pharmaceuticals USA, Inc. $85.5006/15/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749494569 CMS
Teva Pharmaceuticals USA, Inc. $91.2506/15/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749512121 CMS
Teva Pharmaceuticals USA, Inc. $20.0206/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749480017 CMS
Janssen Pharmaceuticals, Inc $18.4006/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719192377 CMS
Janssen Pharmaceuticals, Inc $19.1505/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719192375 CMS
Allergan, Inc. $13.8605/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723761705 CMS
Janssen Pharmaceuticals, Inc $20.0905/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719192383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,298.52 77
PY2020 $10,877.06 129
PY2021 $36,662.63 163
PY2022 $28,312.54 129
PY2023 $54,403.56 173
PY2024 $35,046.15 168
PY2025 $24,059.26 196

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $142,096.33 100
PY2024 Principal investigator $730,402.32 14
PY2023 Recipient $6,845.35 2
PY2023 Principal investigator $2,761,449.90 7
PY2022 Recipient $21,381.00 2
PY2022 Principal investigator $5,458,344.00 4
PY2021 Recipient $224,551.59 2
PY2021 Principal investigator $623,342.53 9
PY2020 Principal investigator $38,884.59 11
PY2019 Principal investigator $291,610.92 28

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

100 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,099.68 12/31/2025 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 to 17 years of age) in the Treatment of Depressive Episodes Associated with Bipolar I Disorder No dispute reported 06/30/2026 1202533857
Principal investigator 1 Boehringer Ingelheim International GmbH $1,090.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683360
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683362
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683364
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683366
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683368
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683370
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683372
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683374
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683376
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683378
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683380
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683382
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683384
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683386
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683388
Principal investigator 1 Boehringer Ingelheim International GmbH $1,090.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683390
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683392
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683394
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683396
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683398
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683400
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683402
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683404
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683406
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683408
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683410
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683412
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683414
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683416
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683418
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683420
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683422
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683424
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683426
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683428
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683430
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683432
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683434
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683436
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683330
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683332
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683334
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683336
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683338
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683340
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683342
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683344
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683346
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683348
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683350
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683352
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683354
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683356
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683358
Principal investigator 1 ABBVIE INC. $2,000.00 09/25/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 1202512276
Principal investigator 1 ABBVIE INC. $2,000.00 09/23/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 1202511876
Principal investigator 1 Boehringer Ingelheim International GmbH $2,951.00 08/22/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683314
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 08/22/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683316
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683318
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 08/22/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683320
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683322
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683324
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683326
Principal investigator 1 ABBVIE INC. $4,826.25 08/06/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 1202503215
Principal investigator 1 Boehringer Ingelheim International GmbH $4,999.00 08/01/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683328
Principal investigator 1 Boehringer Ingelheim International GmbH $2,951.00 07/28/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683294
Principal investigator 1 Boehringer Ingelheim International GmbH $2,951.00 07/28/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683296
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 07/28/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683298
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 07/28/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683300
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 07/28/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683302
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 07/28/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683304
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 07/28/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683306
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 07/28/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683308
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/28/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683310
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/28/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683312
Principal investigator 1 ABBVIE INC. $15,227.75 07/02/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 1202494115
Principal investigator 1 Boehringer Ingelheim International GmbH $2,951.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683268
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683270
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683272
Principal investigator 1 Boehringer Ingelheim International GmbH $2,951.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683274
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683276
Principal investigator 1 Boehringer Ingelheim International GmbH $2,951.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683278
Principal investigator 1 Boehringer Ingelheim International GmbH $2,951.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683280
Principal investigator 1 Boehringer Ingelheim International GmbH $2,951.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683282
Principal investigator 1 Boehringer Ingelheim International GmbH $2,951.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683284
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683286
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683288
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683290
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683292
Principal investigator 1 ABBVIE INC. $8,695.70 06/03/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 1202487781
Principal investigator 1 Boehringer Ingelheim International GmbH $2,951.00 05/27/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683264
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/27/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683266
Principal investigator 1 ABBVIE INC. $750.00 05/07/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 1202483991
Principal investigator 1 Boehringer Ingelheim International GmbH $264.55 03/11/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683438
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 03/03/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683260
Principal investigator 1 Boehringer Ingelheim International GmbH $10,900.00 03/03/2025 Non-covered Recipient Entity
Beaumont Psychiatric Clinic-Jason Mensah DO PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220683262
Principal investigator 1 Eli Lilly and Company $93.75 02/25/2025 Non-covered Recipient Entity
GADOLIN RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187882792
Principal investigator 1 ABBVIE INC. $2,000.00 02/14/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 1202451933
Principal investigator 1 Eli Lilly and Company $15,383.65 02/10/2025 Non-covered Recipient Entity
GADOLIN RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187882944